CJC-1295 Dosing Protocol
CJC-1295 is a GHRH analog available in two forms: with DAC (Drug Affinity Complex) for extended half-life, and without DAC (Mod GRF 1-29) for pulsatile release. Understanding the difference is critical for protocol design.
Key Points
Step-by-Step Guide
Choose Version
With DAC: 8+ day half-life, 2 mg injected 1-2x/week. No DAC (Mod GRF 1-29): 30-minute half-life, 100 mcg injected 1-3x daily, best combined with a GHRP.
Set Schedule
DAC: 2 mg once or twice weekly. No DAC: 100 mcg 1-3x daily on same schedule as ipamorelin. No-DAC preferred for GHRP stacking.
Combine with GHRP
CJC-1295 no DAC is almost always combined with Ipamorelin (200-300 mcg). The combination produces synergistic GH release exceeding either alone.
Follow Fasting Protocol
Same fasting requirements: 2-3 hours without food before, 30 minutes after. Critical for the no-DAC version where the pulse is acute.
Monitor Blood Work
Baseline and follow-up IGF-1 at 4-8 weeks. DAC version produces more sustained IGF-1 elevation. Monitor fasting glucose for insulin sensitivity changes.
Warnings & Precautions
- !Not FDA-approved for any indication.
- !DAC version may suppress natural GH pulsatility.
- !Can cause water retention and joint stiffness.
- !DAC and no-DAC versions are NOT interchangeable in protocols.
Frequently Asked Questions
Which CJC-1295 version is better?
No-DAC is preferred for combining with Ipamorelin due to pulsatile release mimicking natural physiology. DAC is more convenient (1-2 injections/week) but produces less physiological GH elevation.
Can CJC-1295 DAC be used with Ipamorelin?
Some protocols combine them, but this is less common. Sustained DAC elevation may blunt the pulsatile Ipamorelin response. No-DAC is preferred for stacking.
What side effects to watch for?
Water retention, flushing after injection, mild joint stiffness, and tingling in extremities. These indicate GH elevation and typically resolve with dose adjustment.